Procter & Gamble Health financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹364cr+7.4% on Q1 FY26
Net profit
₹96.2cr+45.3% on Q1 FY26
EBITDA margin
27.4%+0.7 pts on Q1 FY26
EPS
₹57.92+45.3% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue364339+7.4%
EBITDA99.690.3+10.3%
EBITDA margin27.4%26.7%+0.7 pts
Profit before tax12988.8+45.4%
Net profit96.266.2+45.3%
EPS₹57.92₹39.87+45.3%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹364 crNet profit₹96.2 crNet margin26.4%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY27Jun 2026FY26Jun 2025FY25Jun 2024FY24Jun 2023FY23 and earlierAlpha Plus
8,962————
FY23 and earlierEvery year the company has filed comes with Alpha Plus.
———239435
1,4333643391,1511,230
—+7.4%−70.6%−6.4%—
46699.690.3306324
32.5%27.4%26.7%26.6%26.4%
44293.684.9279297
35796.266.2201229
24.9%26.4%19.5%17.5%18.7%
₹214.99₹57.92₹39.87₹121.07₹138.23
—+45.3%−67.1%−12.4%—
———228236
———−21.7−42.5
———207194
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

PGHL₹5,399.00

Procter & Gamble Health Limited

· Pharma & Health
₹ CrorePeersSANOFICONRSANOFISENORESINNOVACAPMOREPENLABIOLCPFDCASTRAZENMcap ₹8,962 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY24
30/06/2023
FY25
30/06/2024
FY26
30/06/2025
FY27
30/06/2026
Current/LTM
TTM · last close
Market Capitalization————8,962.3
- Cash, Equiv & ST Investments435.1238.5———
Revenue1,229.61,151.3338.7363.71,432.9
Growth %, YoY—-6.4-70.6+7.4—
EBITDA324.0306.090.399.6465.9
Margin %26.3526.5826.6727.3832.51
EBIT296.6278.684.993.6441.8
Net Income229.5201.066.296.2356.9
Margin %18.6617.4619.5426.4424.91
EPS, Adj (current shares)138.23121.0739.8757.92214.99
Growth %, YoY—-12.4-67.1+45.3—
Cash from Operations236.0228.3———
Capital Expenditures-42.5-21.7———
Free Cash Flow193.5206.6———
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY27 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Procter & Gamble Health financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Procter & Gamble Health (NSE: PGHL) had a market capitalisation of ₹9,152 crore at the 29 October 2026 close (₹5,513.50 a share), a PE ratio of 25.6 on the last four quarters' profit and a price-to-book ratio of 17.45. In the year to June 2026 its consolidated net profit was ₹96.2 crore on revenue of ₹364 crore. It had no borrowings on 31 March 2026. Promoters held 51.82% of the shares on 30 September 2026.

Share price used
₹5,513.50 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Procter & Gamble Health at a glance · consolidated

Market cap
₹9,152 Crat ₹5,513.50 · 29 Oct close
PE ratio (last 4 quarters)
25.695.2 on the year to June 2026 profit
Price to book (PB)
17.45book value ₹315.99 a share
Debt to equity
0.00net cash ₹185 Cr
Promoter holding
51.82%unchanged vs 30 Jun 202630 September 2026
Dividend yield
3.72%₹205 a share in 12 months

Questions

What is the Procter & Gamble Health PE ratio today?

Procter & Gamble Health's PE ratio is 25.6 at the 29 October 2026 close (₹5,513.50 a share): a market capitalisation of ₹9,152 crore divided by consolidated net profit of ₹357 crore over the last four quarters (Q2 FY26 to Q1 FY27). On the year to June 2026 net profit (₹96.2 crore) it is 95.2.

What is the Procter & Gamble Health PB ratio (price to book value)?

Procter & Gamble Health's price-to-book (PB) ratio is 17.45 at the 29 October 2026 close: a market capitalisation of ₹9,152 crore divided by shareholders' equity (book value) of ₹525 crore on 31 March 2026. That is a book value of ₹315.99 per share against a share price of ₹5,513.50.

What is the Procter & Gamble Health dividend yield?

Procter & Gamble Health's dividend yield is 3.72% at the 29 October 2026 close: dividends of ₹205 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹5,513.50. They were ₹45 on 27 August 2026 and ₹160 on 12 February 2026 (interim + special).

What is the Procter & Gamble Health market cap?

Procter & Gamble Health's market capitalisation was ₹9,152 crore at the 29 October 2026 close: 1.66 crore shares at ₹5,513.50 each.

Is Procter & Gamble Health debt free?

Yes. Procter & Gamble Health had no borrowings on 31 March 2026 (consolidated balance sheet), and it held ₹185 crore of cash, bank balances and current investments.

What is the Procter & Gamble Health EPS?

Procter & Gamble Health's basic earnings per share (EPS) were ₹57.92 in the year to June 2026, against ₹39.87 in the year to June 2025. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹214.99.

What is the Procter & Gamble Health debt to equity ratio?

Procter & Gamble Health's debt-to-equity ratio was 0.00 on 31 March 2026: no borrowings against total equity of ₹525 crore. A year earlier, on 31 March 2025, it was 0.00.

What is the Procter & Gamble Health dividend in 2026 and its record date?

In 2026, Procter & Gamble Health has declared two dividends totalling ₹205 a share: ₹160 (interim + special) with record date 12 February 2026 and ₹45 with record date 27 August 2026.

What is the Procter & Gamble Health promoter holding?

Promoters held 51.82% of Procter & Gamble Health on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.

What is the Procter & Gamble Health net worth?

Procter & Gamble Health's net worth — shareholders' equity in its consolidated balance sheet — was ₹525 crore on 31 March 2026, down 2.3% from ₹537 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹9,152 crore at the 29 October 2026 close.

What is the Procter & Gamble Health book value per share?

Procter & Gamble Health's book value per share was ₹315.99 on 31 March 2026: shareholders' equity of ₹525 crore divided by the 1.66 crore shares in issue, down 2.3% from ₹323.47 a year earlier. The share price at the 29 October 2026 close was ₹5,513.50.

What are the Procter & Gamble Health latest quarterly results?

Procter & Gamble Health's latest results are for Q1 FY27 (April–June 2026), filed on 6 August 2026: consolidated net profit ₹96.2 crore, up 45.3% from ₹66.2 crore in Q1 FY26; revenue from operations ₹364 crore, up 7.4% year on year.

What is the Procter & Gamble Health shareholding pattern?

On 30 September 2026, Procter & Gamble Health's shares were held by promoters 51.82%, foreign portfolio investors (FII/FPI) 6.42%, domestic institutions (DII) 12.63% (including mutual funds at 8.89%) and retail and other non-institutional investors 29.13%. Over the year, FII holding was down 0.82 percentage points from 7.24% and DII holding was down 1.28 percentage points from 13.91%.

What is the Procter & Gamble Health revenue and profit in the year to June 2026?

In the year to June 2026 (July 2025–June 2026), Procter & Gamble Health's consolidated net profit was ₹96.2 crore, up 45.3% from ₹66.2 crore in the year to June 2025, on revenue from operations of ₹364 crore (up 7.4%). Over three years, from the year to June 2023, net profit was down 58.1%.

When are the Procter & Gamble Health next results?

Procter & Gamble Health will announce its Q2 FY27 results (July–September 2026) on Monday, 2 November 2026, the date of the board meeting it has notified to the exchanges.

Where do these Procter & Gamble Health figures come from?

From Procter & Gamble Health's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.